NCT07062588View on ClinicalTrials.gov

Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

February 28, 2029

Conditions

Osteogenesis Imperfecta (OI)

Interventions

DRUG

AGA2115

Subcutaneous injection

OTHER

Placebo

Subcutaneous injection

All Listed Sponsors

lead

Angitia Incorporated Limited

INDUSTRY